metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus BSC
	durvalumab plus tremelimumab
	CO.26 study, 2020 JAMA Oncol 2020 Jun 1;6(6):831-838. NCT02870920	RCT	mCRC - 2nd line (L2)	durvalumab plus tremelimumab and BSC	BSC	Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	119 / 61	some concern	inconclusive	suggested 28 % decrease in deaths (OS) (PE)
versus capecitabine, placebo plus bevacizumab
	atezolizumab plus bevacizumab, capecitabine
	BACCI, 2022 JAMA Netw Open 2022; 5:e2149040-. NCT02873195	RCT	mCRC - 2nd line (L2)	capecitabine plus bevacizumab plus atezolizumab	capecitabine plus bevacizumab plus placebo	Patients 18 years and older with Refractory Metastatic Colorectal Cancer	82 / 46	low	inconclusive	inconclusive 27 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE) In this randomized clinical trial, the addition of atezolizumab to capecitabine and bevacizumab therapy provided limited (ie, not clinically meaningful) clinical benefit. Patients with MSS and proficient mismatch repair tumors and those without liver metastasis benefited more
versus regorafenib
	atezolizumab alone
	IMblaze-370 (A ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab monotherapy	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	90 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)
	atezolizumab plus cometinib
	IMblaze-370 (AC ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab plus cometinib	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	183 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)
versus Standard of Care (SoC)
	avelumab alone
	SAMCO-PRODIGE 54, 2023 Dig Liver Dis 2020 Dec 24;S1590-8658(20)31052-5. JAMA Oncol 2023 Oct NCT03186326	RCT	mCRC - 2nd line (L2)	avelumab	FOLFOX if FOLFIRI in first line or FOLFIRI if FOLFOX in first line or Investigator decision if FP in first line /- targeted therapy (panitumab cetuximab bevacizumab aflibercept), 1 treatment every 14 days	2nd Line Treatment in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (dMMR/MSI mCRC) after first line treatment failure	61 / 61	high	inconclusive	no statistically significant result The SAMCO-PRODIGE 54 phase 2 randomized clinical trial showed, in patients with dMMR/MSI mCRC, better PFS and disease control duration with avelumab over standard second-line treatment, with a favorable safety profile.
	nivolumab plus ipilimumab
	CheckMate 8HW, 2024 ASCO ASCO NCT04008030	RCT	mCRC - 2nd line (L2)	nivolumab plus ipilimumab (Arm B)	SOC (ICC), chemo ± targeted therapies	Patients ≥ 18 years with Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) recurrent or not amenable to surgery	171 / 84	NA	conclusif	demonstrated 79 % decrease in progression or deaths (PFS) (PE) suggested 79 % decrease in PFS (extension) NIVO plus IPI demonstrated superior PFS vs chemo in previously untreated pts with MSI-H/dMMR mCRC, Clinical benefit with 1L NIVO plus IPI vs chemo was maintained after subsequent therapy, as shown by improved PFS2 in pts with centrally confirmed MSI-H/dMMR mCRC

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)